血浆和尿 microRNA-483-5p 用于诊断肾上腺皮质癌的比较。
Comparison of plasma and urinary microRNA-483-5p for the diagnosis of adrenocortical malignancy.
机构信息
2nd Department of Internal Medicine, Faculty of Medicine, Semmelweis University, Szentkirályi str. 46., 1088 Budapest, Hungary.
Division of Endocrinology, Diabetes, Metabolism and Nutrition, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905 USA.
出版信息
J Biotechnol. 2019 May 20;297:49-53. doi: 10.1016/j.jbiotec.2019.03.017. Epub 2019 Mar 30.
INTRODUCTION
Minimally invasive circulating microRNAs might be used for the preoperative differentiation of adrenocortical carcinoma (ACC) and adrenocortical adenoma (ACA). So far, the best blood-borne microRNA biomarker of ACC is circulating hsa-miR-483-5p. The expression of urinary hsa-miR-483-5p as a non-invasive marker of malignancy and its correlation with plasma hsa-miR-483-5p, has not been investigated, yet.
AIM
Our aim was to investigate the expression of urinary hsa-miR-483-5p and its correlation with its plasma counterpart.
METHODS
Plasma and urinary samples from 23 ACC and 23 ACA patients were analysed using real-time RT-qPCR. To evaluate the diagnostic applicability of hsa-miR-483-5p, ROC-analysis was performed.
RESULTS
Significant overexpression of hsa-miR-483-5p was observed in carcinoma patients' plasma samples compared to adenoma patients' (p < 0.0001, sensitivity: 87%, specificity: 78.3%). In urinary samples, however, no significant difference could be detected between ACC and ACA patients.
CONCLUSIONS
Plasma hsa-miR-483-5p has been confirmed as significantly overexpressed in adrenocortical cancer patients and thus might be exploited as a minimally invasive preoperative marker of malignancy. The applicability of urinary hsa-miR-483-5p for the diagnosis of adrenocortical malignancy could not be confirmed.
简介
微创循环 microRNAs 可能用于术前鉴别肾上腺皮质癌 (ACC) 和肾上腺皮质腺瘤 (ACA)。到目前为止，ACC 最佳的循环血源性 microRNA 生物标志物是循环 hsa-miR-483-5p。尚未研究尿 hsa-miR-483-5p 作为恶性肿瘤的非侵入性标志物的表达及其与血浆 hsa-miR-483-5p 的相关性。
目的
我们的目的是研究尿 hsa-miR-483-5p 的表达及其与血浆 hsa-miR-483-5p 的相关性。
方法
使用实时 RT-qPCR 分析 23 例 ACC 和 23 例 ACA 患者的血浆和尿液样本。为了评估 hsa-miR-483-5p 的诊断适用性，进行了 ROC 分析。
结果
与腺瘤患者相比，癌患者的血浆样本中 hsa-miR-483-5p 的表达显著上调 (p<0.0001，灵敏度：87%，特异性：78.3%)。然而，在尿样中，无法检测到 ACC 和 ACA 患者之间的显著差异。
结论
血浆 hsa-miR-483-5p 在肾上腺皮质癌患者中被证实显著上调，因此可能被用作微创术前恶性肿瘤标志物。不能证实尿 hsa-miR-483-5p 对肾上腺皮质恶性肿瘤的诊断适用性。
Zotero 插件